Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063870 | 0.76 | RXFP1 (0.41) | HTR1AHTR7KIF11 | |
| SCHEMBL20063370 | 0.74 | SCN9A (0.41) | — | |
| SCHEMBL20095965 | 0.72 | HTR1A (0.55) | HTR1AHTR7HTR2CKDM1AHTR2A | |
| SCHEMBL20095825 | 0.72 | HTR1A (0.55) | HTR1AHTR7HTR2CKDM1AHTR2A | |
| SCHEMBL20096104 | 0.72 | HTR1A (0.55) | HTR1AHTR7HTR2CKDM1AHTR2A | |
| SCHEMBL20063476 | 0.69 | SCN9A (0.51) | HTR2C | |
| SCHEMBL20063372 | 0.69 | SCN9A (0.49) | HTR2C | |
| SCHEMBL20063409 | 0.69 | SCN9A (0.49) | HTR2C | |
| SCHEMBL20063410 | 0.69 | SCN9A (0.49) | HTR2C | |
| SCHEMBL20063450 | 0.69 | SCN9A (0.49) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | HTR1A 931/4885HTR7 853/4885HTR2C 1243/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR1A 955/4885HTR7 884/4885HTR2C 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.